0001553643 false 0001553643 2023-09-05 2023-09-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 5, 2023 

 

RELMADA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-39082   45-5401931
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

2222 Ponce de Leon Blvd., Floor 3

Coral Gables, FL

   33134
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (786) 629 1376

 

 
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol    Name of each exchange on which registered
Common stock, $0.001 par value per share   RLMD   The NASDAQ Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item  5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

On September 5, 2023, Eric Schmidt, a member of the Board of Directors (the “Board”) of Relmada Therapeutics, Inc. (the “Company”), notified the Company that he would resign from the Board, effective immediately. Dr. Schmidt also serves as Chairman of the Audit Committee of the Board and as a member of the Corporate Governance and Nominating Committee of the Board. Dr. Schmidt’s resignation is not due to any disagreement with the Company, the Company’s management or the Board on any matter relating to the Company’s operations, policies or practices. Dr. Schmidt informed the Company that he would leave the Company’s Board due to compliance requirements related to his new role as a sell-side equity analyst at a Wall Street investment banking firm.

 

Dr. Schmidt, a Class I director, has been a Board member since 2019. The Company appreciates his valuable contributions.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: September 6, 2023 RELMADA THERAPEUTICS, INC.
     
  By: /s/ Sergio Traversa
  Name: Sergio Traversa
  Title: Chief Executive Officer

 

 

2

 

 

v3.23.2
Cover
Sep. 05, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 05, 2023
Entity File Number 001-39082
Entity Registrant Name RELMADA THERAPEUTICS, INC.
Entity Central Index Key 0001553643
Entity Tax Identification Number 45-5401931
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 2222 Ponce de Leon Blvd.
Entity Address, Address Line Two  Floor 3
Entity Address, City or Town Coral Gables
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33134
City Area Code 786
Local Phone Number 629 1376
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.001 par value per share
Trading Symbol RLMD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Relmada Therapeutics (NASDAQ:RLMD)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025 Relmada Therapeutics 차트를 더 보려면 여기를 클릭.
Relmada Therapeutics (NASDAQ:RLMD)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025 Relmada Therapeutics 차트를 더 보려면 여기를 클릭.